Urine-based RNA diagnostic marker panel for prostate cancer and use thereof in preparation of prostate cancer diagnostic kit

WO2026237340A1PCT designated stage Publication Date: 2026-11-19CANHELP GENOMICS (SUZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/140656
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2025-12-08
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing urine testing methods for prostate cancer require morning urine or urine after digital rectal examination, have limited gene combinations, insufficient accuracy, are easily affected by other urinary system diseases, and lack sensitivity and specificity, thus failing to meet the clinical needs for early diagnosis.

Method used

A prostate cancer prediction model was constructed by using a combination of 12 genes from urine supernatant and 12 genes from urine sediment, either separately or in combination, to detect RNA markers in ordinary random urine, including 12 genes such as AOX1, C2orf72, and CD24.

Benefits of technology

It requires no morning urine or digital rectal examination, has high sensitivity, specificity and accuracy, can accurately distinguish between prostate cancer and other urinary system diseases, provides early diagnostic evidence, is simple to operate and suitable for clinical application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2025140656_19112026_PF_FP_ABST
    Figure CN2025140656_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided are a urine-based RNA detection marker panel for prostate cancer and a use thereof in preparation of a prostate cancer diagnostic kit. The RNA detection marker panel comprises a urine supernatant 12-gene combination and a urine sediment 12-gene combination. The urine supernatant 12-gene combination and the urine sediment 12-gene combination can be used alone or in combination. The detection marker panel further comprises primers and probes respectively corresponding to the urine supernatant 12-gene combination and the urine sediment 12-gene combination. When the detection marker panel is used for detecting prostate cancer, there is no need to collect first morning urine or urine after a digital rectal examination, and only ordinary random urine is needed, thereby greatly facilitating sample collection and improving the accessibility of detection. Due to a large number of gene combinations, interference of samples on detection results is small, thereby realizing high detection accuracy, high sensitivity and high specificity.
Need to check novelty before this filing date? Find Prior Art

Description

A combination of urine-based prostate cancer RNA diagnostic biomarkers and its application in the preparation of prostate cancer diagnostic kits Technical Field

[0001] This invention relates to the field of early diagnosis of prostate cancer, specifically to a combination of prostate cancer RNA detection biomarkers based on ordinary urine and their application. Background Technology

[0002] Based on the latest data from tumor registry and follow-up surveillance, the National Cancer Center of China released the 2022 China Malignant Tumor Burden Report in JNCC (The Journal of the National Cancer Center). The data shows that in 2022, there were approximately 134,200 new cases of prostate cancer in my country, accounting for 5.3% of all male malignant tumors, and approximately 47,500 deaths, accounting for 2.92% of malignant tumor-related deaths. The incidence and mortality rates of prostate cancer ranked 6th and 7th respectively among male malignant tumors in China.

[0003] Prostate cancer has an insidious onset and atypical early symptoms, making it easily confused with other benign urinary tract diseases. Compared to the high screening rates in Europe and America, prostate cancer in my country is often diagnosed at an advanced stage. Therefore, early diagnosis is crucial for improving the survival rate of prostate cancer patients.

[0004] Currently, the diagnosis of prostate cancer mainly relies on serum PSA (prostate-specific antigen) testing and prostate biopsy performed after digital rectal examination (DRE) assessment. PSA is the first tumor biomarker approved by the U.S. Food and Drug Administration (FDA). A serum PSA level >4 ng / ml is considered elevated, and a PSA level >10 ng / ml indicates a breakdown of the blood-epithelial barrier in the prostate system, increasing the probability of prostate cancer. However, the specificity and sensitivity of serum PSA testing are unsatisfactory, especially when serum PSA levels are in the gray zone (4-10 ng / ml), with only 20%-50% of patients showing a positive prostate cancer result on biopsy. Some benign conditions, such as benign prostatic hyperplasia, prostatitis, and urinary tract infections, can also lead to false positives. Relying solely on PSA for prostate cancer screening may result in excessive biopsies of patients with benign prostate diseases in the gray zone. This can not only cause pain for patients, but may also lead to a series of serious adverse consequences that affect their quality of life, such as bleeding, urinary retention, permanent urinary incontinence, and sexual dysfunction.

[0005] Prostate cancer is a focal lesion, with a large area of ​​histologically normal tissue surrounding the tumor, making it possible to miss the tumor during biopsy. Furthermore, most prostate cancers are indolent, progressing slowly and with a long course. For non-clinically significant prostate cancers, dynamic observation may be an option, while clinically significant prostate cancers require aggressive treatment. However, due to the influence of the biopsy site and tissue size, there is a lack of consistency between biopsy scores and Gleason grading (prostate cancer scoring system) scores. According to Cheng Wanli, Pang Cheng, Song Xinda, et al., "Analysis of Risk Factors for Upgrade of Postoperative Pathological Gleason Score in Low-Risk Prostate Cancer" ([J]. Chinese Journal of Geriatrics, 2020, 39(9):1059-1062.DOI:10.3760 / cma.j.issn.0254-9026.2020.09.016), 50% of patients with a biopsy Gleason score of 6 experienced postoperative pathological upgrade. The inconsistency between biopsy Gleason score and radical prostatectomy Gleason score is one of the important issues in the clinical treatment of prostate cancer. Therefore, risk stratification of prostate cancer patients and identification of clinically significant prostate cancer are crucial for prostate cancer management.

[0006] Previous studies have shown that prostate cancer cells can release tumor markers into prostatic fluid, which then enters the urine. Therefore, prostate cancer tumor markers can be detected through urine. The PCA3 (prostate cancer associated 3 Gene) score is the first FDA-approved urine-based tumor marker-based test. It quantitatively measures the concentrations of PCA3 and PSAmRNA (Messenger RNA, mRNA) in urine after a digital rectal examination; the ratio of these two concentrations is the PCA3 score. Additionally, Bio-Techne's ExoDx Prostate IntelliScore product uses exosome RNA in urine to predict the risk of prostate cancer in patients with PSA in the gray zone, specifically predicting whether they have high-grade, more aggressive prostate cancer. Therefore, urine-based adjunctive diagnosis of prostate cancer is indeed feasible.

[0007] Several invention patents have been granted to address the issue of early diagnosis of prostate cancer. For example:

[0008] Patent CN116377068A discloses NKX3-1, an RNA biomarker for prostate cancer in urine. This patent, by comparing the urine of prostate cancer patients and healthy individuals, found that NKX3-1 is highly expressed in prostate cancer patients and expressed at lower levels in healthy individuals, thus enabling the detection of prostate cancer using only urine samples. However, this patent can only differentiate between prostate cancer and healthy individuals, and its effectiveness is still influenced by other urinary system diseases.

[0009] Patent CN118562932A discloses a urine RNA preservation solution, a urine RNA extraction kit, and the application of a combination of PCA3, HOXC6, and DLX1 genes in early prostate cancer screening. It provides a method with high accuracy and specificity, simple operation, low cost, and the ability to use morning urine samples instead of DRE urine samples, reducing patient sampling discomfort and improving patient compliance. However, this patent still requires the collection of morning urine and cannot use ordinary random urine.

[0010] Therefore, in summary, existing urine-based prostate cancer detection methods have the following problems.

[0011] First, the requirements for test samples are quite high, often requiring first-morning urine or urine collected after a digital rectal examination. This significantly limits the practicality of the screening and reduces the accuracy of sampling. Some elderly patients have a habit of urinating at night, making it difficult to collect qualified first-morning urine.

[0012] Secondly, the limited number of gene combinations used in the test results makes the sample more susceptible to interference with the test results, thus affecting the accuracy of the test.

[0013] Third, the detection accuracy is not ideal, with insufficient sensitivity and specificity, often falling below 80%, and the accuracy also needs further improvement.

[0014] Fourth, detection using only a single biomarker provides limited information. While it can differentiate between prostate cancer patients and healthy individuals, it is often affected by other urological diseases and cannot accurately reflect the development and progression of prostate cancer, thus failing to be truly applicable to clinical prostate cancer screening. Summary of the Invention

[0015] To address the aforementioned issues, this invention proposes a combination of prostate cancer RNA biomarkers based on ordinary urine. The biomarkers of this invention can be detected using ordinary random urine, eliminating the need for morning urine or urine collected after digital rectal examination, which greatly facilitates sample collection. Furthermore, this invention uses a large number of biomarkers that have been scientifically screened, resulting in high detection sensitivity, specificity, and accuracy.

[0016] The technical solution of this invention is: a combination of prostate cancer RNA detection biomarkers based on urine, wherein the combination of RNA detection biomarkers includes a combination of 12 genes in urine supernatant and a combination of 12 genes in urine sediment; wherein, the combination of 12 genes in urine supernatant includes AOX1 gene, C2orf72 gene, CYP3A5 gene, FA2H gene, LOC105370113 gene, TNFRSF19 gene, MIPEP gene, MX2 gene, NSG1 gene, PCA3 gene, PCOTH gene, and S100A4 gene; and the combination of 12 genes in urine sediment includes AGPAT4 gene, CD24 gene, CRABP2 gene, CTSK gene, FDFT1 gene, GDPD3 gene, KAT2B gene, MFSD13A gene, PLS3 gene, SDC3 gene, TLE2 gene, and UCA1 gene.

[0017] The urine supernatant 12 gene combination and the urine sediment 12 gene combination can be used individually or in combination.

[0018] The genes and corresponding primers in the urinary supernatant 12 gene combination are shown in Table 1.

[0019] Table 1

[0020] The genes and corresponding primers of the urinary sediment 12 genome are shown in Table 2.

[0021] Table 2

[0022] Furthermore, this invention also discloses the application of a urine-based prostate cancer RNA detection marker composition in the preparation of a prostate cancer diagnostic kit, wherein the detection marker composition comprises primers and probes corresponding to the 12 gene combinations in the urinary supernatant as shown in Table 3 below:

[0023] Table 3

[0024] Furthermore, the detection marker composition also includes primers and probes corresponding to the urinary sediment 12 gene combinations listed in Table 4 below:

[0025] Table 4

[0026] The primers and probes corresponding to the urinary supernatant 12 gene combination and the urinary sediment 12 gene combination can be used individually or in combination.

[0027] The urine sample mentioned herein is random urine. Unlike many existing prostate cancer detection reagents and methods, which require morning urine or urine obtained after digital rectal examination, this invention only requires ordinary random urine.

[0028] This invention employs 12 RNA markers for urine supernatant and urine sediment, including the AGPAT4 gene, AOX1 gene, C2orf72 gene, CD24 gene, CRABP2 gene, CTSK gene, CYP3A5 gene, FA2H gene, FDFT1 gene, GDPD3 gene, KAT2B gene, LOC105370113 gene, MFSD13A gene, MIPEP gene, MX2 gene, NSG1 gene, PCA3 gene, PCOTH gene, PLS3 gene, S100A4 gene, SDC3 gene, TLE2 gene, TNFRSF19 gene, and UCA1 gene.

[0029] Through the above gene combination, the present invention can accurately distinguish between prostate cancer and other prostate diseases, which meets the actual needs of clinical practice.

[0030] The sequences of the aforementioned gene markers are publicly available in biological databases. For example, they can be obtained by entering the sequence number into the Nuleotide (RefSeq) database on the NCBI (National Center for Biotechnology Information) website. For instance, the sequence information for AOX1 can be obtained as follows: https: / / www.ncbi.nlm.nih.gov / nuccore / NM_001159.4.

[0031] The detection method for RNA biomarkers in urine supernatant and urine sediment proposed in this paper can be used alone or in combination.

[0032] Compared with existing technologies, the present invention provides a prostate cancer RNA detection biomarker and method based on ordinary urine, which has the following beneficial effects:

[0033] 1. This invention eliminates the need to collect morning urine or urine after digital rectal examination; only ordinary random urine is required, which greatly facilitates sample collection and improves the accessibility of testing and the possibility of widespread application.

[0034] 2. Twelve RNA biomarkers were used for both urine supernatant and urine sediment, resulting in a wide variety of gene combinations and minimal interference from the sample with the test results, thus improving the accuracy of the test.

[0035] 3. By detecting multiple RNA markers in urine supernatant and urine sediment, the occurrence and development of prostate cancer can be comprehensively reflected, providing an important basis for the early diagnosis and treatment of the disease;

[0036] 4. The detection method is simple to operate, requiring no complicated sample pretreatment and experimental conditions. It can be used alone or in combination with urine supernatant samples, which is conducive to clinical application.

[0037] The combination of detection markers in this invention has high sensitivity, specificity, and detection accuracy. Attached Figure Description

[0038] Figure 1 is the AUROC plot of the urine sediment sample from Example 2.

[0039] Figure 2 is the AUROC plot of the urine supernatant sample from Example 3.

[0040] Figure 3 is an AUROC plot comparing the results of RNA markers in urine sediment from Example 5 with those of PSA and PI-RADS detection.

[0041] Figure 4 is an AUROC plot comparing the results of RNA markers in urine supernatant from Example 5 with those of PSA and PI-RADS detection.

[0042] Figure 5 is an AUROC plot comparing the results of RNA markers from urine sediment and urine supernatant integrated in Example 5 with those from PSA and PI-RADS detection. Detailed Implementation

[0043] The technical solution of the present invention will be further described below with reference to specific embodiments, but the present invention is not limited to these embodiments.

[0044] Example 1: Screening of gene combinations

[0045] 1. Study population

[0046] Patients who visited Fudan University Cancer Hospital for urinary system diseases in 2024 were selected as the study subjects. The inclusion criteria for this study were:

[0047] Inclusion criteria:

[0048] 1) Age ≥ 18 years;

[0049] 2) Urine sample volume ≥ 50 mL;

[0050] 3) Meet one of the following conditions:

[0051] a. Patients who are suspected of having prostate cancer due to elevated PSA, positive digital rectal examination, or imaging findings, and who are scheduled to undergo prostate biopsy to confirm the diagnosis;

[0052] b. Patients diagnosed with prostate cancer by prostate biopsy and who are scheduled for radical prostatectomy and / or endocrine therapy or radiation therapy;

[0053] c. Patients clinically diagnosed with benign urinary system diseases, including: benign prostatic hyperplasia, prostatitis, urinary tract stones, renal cysts, ureteral stricture, urethral stricture, hypospadias, urinary tract infection, glandular cystitis and other benign urinary system diseases;

[0054] d. Patients with other tumors diagnosed clinically or pathologically as not being prostate cancer, including bladder cancer, kidney cancer, ureteral cancer, renal pelvis cancer, etc.

[0055] Exclusion criteria:

[0056] 1) Patients who have previously undergone transurethral resection or enucleation of the prostate, or radiotherapy to the prostate;

[0057] 2) The patient has previously received endocrine therapy, or has taken a 5α-reductase inhibitor within the past 6 months;

[0058] 3) Any other circumstances that the researchers believe make them unsuitable to participate in the trial.

[0059] Patients were drawn from the outpatient or inpatient urology department of Fudan University Cancer Hospital. This study was approved by the hospital's ethics committee, and all participants signed informed consent forms.

[0060] 2. Experimental Methods

[0061] 1) Urine collection

[0062] Approximately 50-120 mL of random urine was collected from the study subjects using a urine cup.

[0063] 2) Urine pretreatment

[0064] Place freshly collected urine into a 50mL centrifuge tube and centrifuge at 1500g for 15min to obtain urine sediment (for later use) and supernatant.

[0065] Transfer the supernatant to a new 50mL centrifuge tube, centrifuge at 3000g for 15min, discard the bottom, and transfer the second supernatant to a new 50mL centrifuge tube for later use (15-20mL / tube). 3) Enrichment of urine cfRNA (cell-free RNA, abbreviated as cfRNA)

[0066] Mix the urine and precipitant (16% PEG) (Polyethylene glycol) at a ratio of approximately 1:1, and allow to precipitate overnight at 4°C.

[0067] Centrifuge the 50mL centrifuge tube after precipitation at 3000g for 1 hour at 4℃, carefully remove the supernatant, and keep the remaining precipitate for later use.

[0068] 4) Extraction of cfRNA from urine sediment and supernatant

[0069] Take the urine sediment and supernatant, add 1 mL of Trizol (Trizol reagent, total RNA extraction reagent) and mix well. Then add 200 μL of chloroform to the centrifuge tube, vortex to mix thoroughly, and centrifuge at 12000 rpm for 15 min to separate the layers.

[0070] Gently aspirate the colorless, transparent liquid from the top layer into a new centrifuge tube, add an equal volume of ethanol, and mix well.

[0071] RNA was extracted using a purification column method.

[0072] 5) RNA sequencing

[0073] mRNA was enriched from total RNA using thymine-based nucleotide chains (Oligo dT) magnetic beads. After fragmentation, first-strand cDNA was synthesized using random hexamer primers, followed by second-strand cDNA synthesis. After end repair, A-tailing, adapter ligation, fragment selection, amplification, and purification, the library was ready.

[0074] The above library was sequenced using an Illumina Novaseq 6000 sequencer, with a sequencing data volume of 6 GB (GB, a unit of gene length, representing 1000 MB). The high-throughput sequencing data was analyzed using the FastQ program.

[0075] 6) Mining of biomarkers

[0076] Data from different levels (urine sediment and cfRNA in urine supernatant) were divided into two groups: a prostate cancer group and a control group. Based on the relative expression levels of each biomarker in the prostate cancer group and the control group, statistical methods were used to mine RNA biomarkers that can be used to distinguish between prostate cancer and non-prostate cancer.

[0077] 7) Construct a prostate cancer prediction model

[0078] Table 5. Gene combinations of 12 genes in urine supernatant

[0079] The primers and probes corresponding to the urinary supernatant 12 gene are shown in Table 6.

[0080] Table 6

[0081] Table 7. Gene Combinations of Urinary Sediment

[0082] The primers and probes corresponding to the 12 genes in urine sediment are shown in Table 8.

[0083] Table 8

[0084] 8) Use the prostate cancer prediction model constructed above to test new urine samples.

[0085] Example 2 uses RNA markers from urine sediment for detection.

[0086] In this embodiment, 108 random urine samples were analyzed from 54 patients with prostate cancer (43 of whom had a Gleason score ≥7) and 54 patients without prostate cancer but with other urinary system diseases (controls). Twelve RNA biomarkers from urinary sediment were used to analyze the samples. The results are shown in Table 9.

[0087] Table 9 Performance of 12-gene combination analysis in urinary sediment

[0088] For these 108 samples, the sensitivity of this invention was 77.78%, the specificity was 81.48%, and the AUROC (Area Under Receiver Operating Characteristic Curve) reached 0.8563. The results are shown in Figure 1.

[0089] For aggressive prostate cancer (Gleason score ≥ 7), the detection accuracy was 83.72% (36 / 43).

[0090] Example 3 uses RNA markers from urine supernatant

[0091] In this embodiment, 102 random urine samples were analyzed from 52 patients with prostate cancer (40 of whom had a Gleason score ≥7) and 50 patients without prostate cancer but with other urinary system diseases (controls). Twelve RNA biomarkers from the urinary supernatant were used to analyze the samples. The results are shown in Table 10.

[0092] Table 10 Performance of 12-gene combination analysis in urine supernatant

[0093] For these 102 samples, the sensitivity of this invention was 80.77%, the specificity was 86.00%, and the AUROC reached 0.8746.

[0094] For aggressive prostate cancer (Gleason score ≥ 7), the detection accuracy was 87.50% (35 / 40). The results are shown in Figure 2.

[0095] Example 4: Combined use of RNA markers from urine sediment and urine supernatant

[0096] A total of 152 random urine samples were collected from 81 patients with prostate cancer (64 of whom had a Gleason score ≥7) and 71 patients without prostate cancer but with other urinary system diseases (controls). A combined detection method using urine sediment and urine supernatant RNA was employed. A positive result was defined as a positive result from either urine sediment or urine supernatant. The results are shown in Table 11.

[0097] Table 11

[0098] For these 152 samples, the sensitivity of this invention was 83.95%, the specificity was 80.28%, and the accuracy was 82.24%.

[0099] For aggressive prostate cancer (Gleason score ≥ 7), the detection accuracy was 90.63% (58 / 64).

[0100] Example 5: Comparison of the RNA biomarkers of the present invention with commonly used clinical indicators (PSA and PI-RADS)

[0101] PI-RADS, or Prostate Imaging Reporting and Data System, is a system for standardizing the reporting of prostate magnetic resonance imaging (MRI) scans, designed to improve the accuracy and consistency of prostate cancer diagnosis. "PSA" and "MRI (i.e., PI-RADS indicators)" are common biomarkers and imaging tools in prostate cancer diagnosis.

[0102] PSA is an important indicator for prostate cancer screening. When its level is abnormally elevated, it suggests a possible risk of prostate cancer, and further examination is needed to confirm the diagnosis.

[0103] MRI is an imaging examination that can provide more intuitive information about tumors, but it also presents certain diagnostic challenges in practical applications, such as how to distinguish between benign and malignant lesions.

[0104] PI-RADS scores range from 1 to 5, where...

[0105] PI-RADS 1: Very low risk, almost impossible to have clinically significant prostate cancer.

[0106] PI-RADS 2: Low risk, unlikely to have clinically significant prostate cancer.

[0107] PI-RADS 3: Intermediate risk, with possible or absent clinically significant prostate cancer.

[0108] PI-RADS 4: High risk, likely clinically significant prostate cancer.

[0109] PI-RADS 5: Very high risk, highly probable clinically significant prostate cancer.

[0110] For the 152 samples in Example 4, their clinical data were collected, and PSA and PI-RADS results were obtained. The results of the RNA markers of urine sediment constructed in this invention were compared with the PSA and PI-RADS detection results, as shown in Table 12 and Figure 3.

[0111] Table 12

[0112] The results of the RNA markers in urine supernatant constructed using the present invention are compared with the results of PSA and PI-RADS detection, as shown in Table 13 and Figure 4.

[0113] Table 13

[0114] The results of the integrated analysis of RNA markers in urine sediment and urine supernatant constructed using the present invention are compared with the results of PSA and PI-RADS detection, as shown in Table 14 and Figure 5.

[0115] Table 14

[0116] Note: A positive result is considered a positive result if either the urine supernatant or the urine sediment is positive.

[0117] As can be seen from the comparison of Example 5:

[0118] 1) The AUROC values ​​of the RNA markers of this invention are all maximum.

[0119] 2) The detection results of the RNA biomarkers of this invention are superior to those of the PI-RADS scoring system.

[0120] 3) PSA testing has high sensitivity and can detect most prostate cancer patients. However, PSA testing has relatively low specificity and is easily affected by various factors, such as benign prostatic hyperplasia and prostatitis. This may lead to false positive results. The RNA biomarker of this invention maintains high sensitivity while also achieving a specificity of 80%, resulting in the highest overall accuracy.

[0121] This invention employs 12 RNA biomarkers from urine supernatant and urine sediment. These biomarkers can be used individually or in combination. The invention offers a wide range of gene combinations, minimizes sample interference with test results, and provides high sensitivity. It can accurately distinguish between prostate cancer and other urinary system diseases, while maintaining a good balance between sensitivity and specificity, resulting in high detection accuracy.

[0122] This invention eliminates the need to collect morning urine or urine after digital rectal examination; only ordinary random urine is required, which greatly facilitates sample collection and improves the accessibility of testing and the possibility of widespread application.

[0123] The above description is only a preferred embodiment of the present invention. It should be noted that those skilled in the art can make several modifications and improvements without departing from the inventive concept of the present invention, and these all fall within the protection scope of the present invention.

Claims

1. A urine-based prostate cancer RNA detection marker combination, characterized by, The RNA detection biomarker combination consists of a urine supernatant 12 gene combination and a urine sediment 12 gene combination; wherein, the urine supernatant 12 gene combination is a combination of AOX1 gene, C2orf72 gene, CYP3A5 gene, FA2H gene, LOC105370113 gene, TNFRSF19 gene, MIPEP gene, MX2 gene, NSG1 gene, PCA3 gene, PCOTH gene, and S100A4 gene; and the urine sediment 12 gene combination is a combination of AGPAT4 gene, CD24 gene, CRABP2 gene, CTSK gene, FDFT1 gene, GDPD3 gene, KAT2B gene, MFSD13A gene, PLS3 gene, SDC3 gene, TLE2 gene, and UCA1 gene.

2. The combination of prostate cancer RNA detection markers according to claim 1, characterized in that, The urine supernatant 12 gene combination and the urine sediment 12 gene combination can be used individually or in combination.

3. A reagent combination for detecting the prostate cancer RNA detection marker combination according to claim 1, characterized by The reagent combination comprises primers and probes corresponding to the following table for the 12-gene combination of urine supernatant:

4. The combination of agents according to claim 3, characterized in that, The reagent combination also comprises primers and probes corresponding to the following table for the urinary sediment 12 gene combination:

5. Use of a combination of detection reagents in the preparation of a diagnostic kit for prostate cancer, characterized in that, The detection reagent combination is used for detecting the prostate cancer RNA detection marker combination of claim 1, and the detection reagent combination comprises primers and probes corresponding to the urine supernatant 12 gene combination as shown in the following table: and the detection reagent set further comprises primers and probes corresponding to the urinary sediment 12 gene set as described in the following table: The primers and probes corresponding to the urinary supernatant 12 gene combination and the urinary sediment 12 gene combination can be used individually or in combination.

6. Use of the urine-based prostate cancer RNA detection marker composition according to claim 1 in the manufacture of a diagnostic kit for prostate cancer, characterized in that, The urine sample is a random sample.